Baxalta

Baxalta

Type	Subsidiary
Key people	Ludwig Hantson (CEO)
Industry	Biotechnology
Products	Hemophilia treatments, immunology products

Baxalta Incorporated was a biopharmaceutical company that specialized in developing and marketing therapies for hematology, immunology, and oncology. It was established in 2015 as a spin-off from Baxter International.

History

Baxalta was created when Baxter International decided to spin off its biopharmaceutical division to focus on its medical products business. The spin-off was completed on July 1, 2015, and Baxalta began trading on the New York Stock Exchange under the ticker symbol BXLT.

In January 2016, Shire announced it would acquire Baxalta for $32 billion. The acquisition was completed in June 2016, and Baxalta became a wholly owned subsidiary of Shire.

Products

Baxalta's product portfolio included treatments for hemophilia, immune disorders, and cancer. Some of its notable products were:

• Advate - a recombinant antihemophilic factor for hemophilia A
• Gammagard - an immunoglobulin therapy for primary immunodeficiency
• Oncaspar - a treatment for acute lymphoblastic leukemia

Research and Development

Baxalta invested heavily in research and development to expand its product offerings and improve existing therapies. The company focused on developing treatments for rare and orphan diseases, leveraging its expertise in biotechnology and genetic engineering.

See also

• Baxter International
• Shire (pharmaceutical company)
• Biotechnology
• Pharmaceutical industry

References

<references />

External links

• [Official website of Shire](https://www.shire.com)

Baxalta

• 
  Baxalta logo